ALKS Share Price

Open 57.22 Change Price %
High 57.91 1 Day 0.13 0.23
Low 56.19 1 Week 0.40 0.71
Close 57.13 1 Month -2.22 -3.74
Volume 560142 1 Year 16.56 40.82
52 Week High 62.50
52 Week Low 36.71
ALKS Important Levels
Resistance 2 58.72
Resistance 1 58.07
Pivot 57.08
Support 1 56.19
Support 2 55.54
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
SIRI 5.11 -1.73%
STX 42.01 -16.83%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CMLS 0.28 21.74%
ZAZA 0.06 20.00%
CONN 17.50 18.24%
CONN 17.50 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Alkermes plc (NASDAQ: ALKS)

ALKS Technical Analysis 2
As on 26th Apr 2017 ALKS Share Price closed @ 57.13 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 51.83 & Sell for SHORT-TERM with Stoploss of 57.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
ALKS Target for April
1st Target up-side 62.97
2nd Target up-side 66.1
3rd Target up-side 69.23
1st Target down-side 54.03
2nd Target down-side 50.9
3rd Target down-side 47.77
ALKS Other Details
Segment EQ
Market Capital 2719078400.00
Sector Healthcare
Industry Drug Delivery
Offical website http://www.alkermes.com
ALKS Address
ALKS
Connaught House
1 Burlington Road
Dublin, 4
Ireland
Phone: 353 1 772 8000
ALKS Latest News
Interactive Technical Analysis Chart Alkermes plc ( ALKS NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alkermes plc
ALKS Business Profile
Alkermes Public Limited Company, incorporated on May 4, 2011, is an integrated, global biopharmaceutical company. The Company has a portfolio of more than 20 commercial drug products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders such as addiction, schizophrenia and depression. The Company manufactures RISPERDAL CONSTA, VIVITROL and polymer for BYDUREON in its Wilmington, Ohio facility. The Company operates PERDAL CONSTA lines and one VIVITROL line at commercial scale. The Company manufactures AMPYRA/FAMPYRA, RAPAMUNE and other products in its Athlone, Ireland facility. It manufactures FOCALIN XR, RITALIN LA, AVINZA, VERAPAMIL and other products in its Gainesville, Georgia facility. The Company’s RISPERDAL CONSTA (risperidone long-acting injection) and INVEGA SUSTENNA/XEPLION (paliperidone palmitate extended-release injectable suspension) are long-acting atypical antipsychotics that incorporate its technologies. RISPERDAL CONSTA uses its polymer-based microsphere injectable extended-release technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. RISPERDAL CONSTA is manufactured by the Company and is marketed and sold by Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International, a division of Cilag International AG (Janssen) around the globe. INVEGA SUSTENNA uses its nanoparticle injectable extended-release technology to increase the rate of dissolution and enable the formulation of an aqueous suspension for once-monthly intramuscular administration.